Market Overview

UPDATE: Bank of America Upgrades Mindray Medical International to Buy; Selloff Creates Opportunity

Related MR
Earnings Scheduled For August 10, 2015
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio

Bank of America raised its rating on Mindray Medical International (NYSE: MR) from Neutral to Buy and increased its price objective from $35 to $36.

Bank of America noted, "MR share were sharply down (-8%) in the last trading session due to resurfaced concerns on US business slow down and NA management uncertainty. We upgrade MR to Buy and raise our PO to US$36 as (1) we believe the selloff is overdone and offers buying opportunity as the shares become attractively valued at 15x 2013PE; (2) we believe MR should be able to reaffirm its 2012 guidance and offer benign 2013 forecast next week at a global healthcare conference which could provide support to the share price; (3) Mindray is fundamentally a solid leader in the medical equipment sector with relatively low policy risk as compared with its peers in the China healthcare sector."

Mindray Medical International closed at $30.17 on Wednesday.

Latest Ratings for MR

Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MR)

Get Benzinga's Newsletters